机构:[1]Department of Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.临床科室肿瘤内科河北医科大学第四医院[2]Department of urology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.临床科室泌尿外科河北医科大学第四医院[3]Research Center, Hebei Province Hospital of Chinese Medicine, Affiliated Hospital of Hebei University of Traditional Chinese Medicine, Shijiazhuang, Hebei, China. Department of Pathology and Laboratory Medicine, Department of Pathology, Kanazawa Medical University, Uchinada, Ishikawa, Japan.河北大学附属医院[4]Department of anesthesiology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.临床科室麻醉科河北医科大学第四医院[5]Department of radiotherapy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.河北医科大学第四医院[6]Department of ophthalmology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.临床科室眼科河北医科大学第四医院
第一作者机构:[1]Department of Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
共同第一作者:
通讯作者:
通讯机构:[2]Department of urology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.[*1]Department of urology, The Fourth Hospital of Hebei Medical University, 12 Jiankang Road, 050000 Shijiazhuang, China
推荐引用方式(GB/T 7714):
Jin Hui,Liu Bin,Guo Xin,et al.MYLK and CALD1 as molecular targets in bladder cancer[J].MEDICINE.2023,102(47):e36302.doi:10.1097/MD.0000000000036302.
APA:
Jin Hui,Liu Bin,Guo Xin,Qiao Xi,Jiao Wenpeng...&Jin Tingting.(2023).MYLK and CALD1 as molecular targets in bladder cancer.MEDICINE,102,(47)
MLA:
Jin Hui,et al."MYLK and CALD1 as molecular targets in bladder cancer".MEDICINE 102..47(2023):e36302